Journal of the American Society of Hypertension
Volume 3, Issue 6 , Pages 353-365 , November 2009

The complex interaction between overweight, hypertension, and sympathetic overactivity

  • Carlos Feldstein, MD

      Affiliations

    • Hypertension Program, Department of Medicine, Buenos Aires University, Hospital de Clínicas José de San Martín, Buenos Aires, Argentina
    • ,
  • Stevo Julius, MD, ScD

      Affiliations

    • Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, USA
    • Corresponding Author InformationCorresponding author: Stevo Julius MD, ScD, Division of Cardiovascular Medicine, University of Michigan, 24 Frank Lloyd Wright Dr., Lobby M, 3rd Fl., Ann Arbor, MI 48106. Tel: 734-998-7955; fax: 734-998-8018.

Received 26 August 2009 ,Accepted 1 October 2009.

References 

  1. In:  Guyton AC,  Hall JE editor. Textbook of medical physiology. 11th ed. Philadelphia: WB Saunders; 2006;p 881-8
  2. Landsberg L, Saville ME, Young JB. Sympathoadrenal system and regulation of thermogenesis. Am J Physiol. 1984;247(2 Pt 1):E181–E189
  3. Scherrer U, Randin D, Tappy L, Vollenweider P, Jéquier E, Nicod P. Body fat and sympathetic nerve activity in healthy subjects. Circulation. 1994;89:2634–2640
  4. Poehlman ET, Gardner AW, Goran MI, Arciero PJ, Toth MJ, Ades PA, et al. Sympathetic nervous system activity, body fatness, and body fat distribution in younger and older males. J Appl Physiol. 1995;78:802–806
  5. Paolisso G, Manzella D, Ferrara N, Gambardella A, Abete P, Tagliamonte MR, et al. Glucose ingestion affects cardiac ANS in healthy subjects with different amounts of body fat. Am J Physiol. 1997;273(3 Pt 1):E471–E478
  6. Blaak EE, van Baak MA, Kempen KP, Saris WH. Role of alpha- and beta- adrenoceptors in sympathetically mediated thermogenesis. Am J Physiol. 1993;264(1Pt 1):E11–E17
  7. Sjöström L, Schutz Y, Gudinchet F, Hegnell L, Pittet PG, Jéquier E. Epinephrine sensitivity with respect to metabolic rate and other variables in women. Am J Physiol. 1983;245(5 Pt 1):E431–E442
  8. Webber J, Taylor J, Greathead H, Dawson J, Buttery PJ, Macdonald IA. A comparison of the thermogenic, metabolic and haemodynamic responses to infused adrenaline in lean and obese subjects. Int J Obes Relat Metab Disord. 1994;18:717–724
  9. Welle S, Schwartz RG, Statt M. Reduced metabolic rate during beta-adrenergic blockade in humans. Metabolism. 1991;40:619–622
  10. Zurlo F, Larson K, Bogardus C, Ravussin E. Skeletal muscle metabolism is a major determinant of resting energy expenditure. J Clin Invest. 1990;86:1423–1427
  11. Ravussin E, Bogardus C. A brief overview of human energy metabolism and its relationship to essential obesity. Am J Clin Nutr. 1992;55:242S–245S
  12. Simonsen L, Stallknecht B, Bülow J. Contribution of skeletal muscle and adipose tissue to adrenaline-induced thermogenesis in man. Int J Obes. Relat Metab Disord. 1993;17(Suppl 3):S47–S51
  13. Simonsen L, Bülow J, Madsen J, Christensen NJ. Thermogenic response to epinephrine in the forearm and abdominal subcutaneous adipose tissue. Am J Physiol. 1992;263(5 Pt 1):E850–E855
  14. Lean ME. Brown adipose tissue in humans. Proc Nutr Soc. 1989;48:243–256
  15. Krief S, Lönnqvist F, Raimbault S, Baude B, Van Spronsen A, Arner P, et al. Tissue distribution of beta 3-adrenergic receptor mRNA in man. J Clin Invest. 1993;91:344–349
  16. Virtanen K, Lidell M, Orava J, Heglind M, Westergren R, Niemi T, et al. Functional brown adipose tissue in healthy adults. N Engl J Med. 2009;360:1518–1525
  17. van Marken Lichtenbeit WD, Vanhommering JW, Smulders NM, Drossaerts JMAFL, Kemerink GJ, Bouvy N, et al. Cold-activated brown adipose tissue in healthy men. N Engl J Med. 2009;360:1500–1509
  18. Acheson KJ, Ravussin E, Wahren J, Jéquier E. Thermic effect of glucose in man. Obligatory and facultative thermogenesis. J Clin Invest. 1984;74:1572–1580
  19. Young JB, Landsberg L. Suppression of sympathetic nervous system during fasting. Science. 1977;196:1473–1475
  20. Young JB, Landsberg L. Stimulation of the sympathetic nervous system during sucrose feeding. Nature. 1977;269:615–617
  21. Landsberg L, Young JB. Diet and the sympathetic nervous system: relationship to hypertension. Int J Obes. 1981;5:79–91
  22. Landsberg L. Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q J Med. 1986;61:1081–1090
  23. Astrup A, Bülow J, Christensen NJ, Madsen J, Quaade F. Facultative thermogenesis induced by carbohydrate: a skeletal muscle component mediated by epinephrine. Am J Physiol. 1986;250(2Pt 1):E226–E229
  24. Schwartz RS, Jaeger LF, Silberstein S, Veith RC. Sympathetic nervous system activity and the thermic effect of feeding in man. Int J Obes. 1987;11:141–149
  25. Landsberg L, Young JB. Sympathoadrenal activity and obesity: physiological rationale for the use of adrenergic thermogenic drugs. Int J Obes Relat Metab Disord. 1993;17(Suppl 1):S29–S34
  26. Landsberg L, Young JB. The role of the sympathoadrenal system in modulating energy expenditure. In:  James WPT editors. Clinics in endocrinology and metabolism obesity. London: WB Saunders; 1984;p. 475–499
  27. Landsberg L, Young JB. Autonomic regulation of thermogenesis. In:  Girardier L,  Stock MJ editor. Mammalian thermogenesis. London: Chapman and Hall; 1983;p. 99–140
  28. Young JB, Landsberg L. Impaired suppression of sympathetic activity during fasting in the gold thioglucose-treated mouse. J Clin Invest. 1980;65:1086–1094
  29. Rowe JW, Young JB, Minaker KL, Stevens AL, Pallotta J, Landsberg L. Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes. 1981;30:219–225
  30. Hausberg M, Mark AL, Hoffman RP, Sinkey CA, Anderson EA. Dissociation of sympathoexcitatory and vasodilator actions of modestly elevated plasma insulin levels. J Hypertension. 1995;13:1015–1021
  31. DeFronzo RA, Thorin D, Felber JP, Simonson DC, Thiebaud D, Jequier E, et al. Effect of beta and alpha adrenergic blockade on glucose-induced thermogenesis in man. J Clin Invest. 1984;73:633–639
  32. Ward KD, Sparrow D, Landsberg L, Young JB, Vokonas PS, Weiss ST. Influence of insulin, sympathetic nervous system activity, and obesity on blood pressure: the Normative Aging Study. J Hypertens. 1996;14:301–308
  33. Rumantir MS, Vaz M, Jennings GL, Collier G, Kaye DM, Seals DR, et al. Neural mechanisms in human obesity-related hypertension. J Hypertens. 1999;17:1125–1133
  34. Corry DB, Tuck ML. Obesity, hypertension, and sympathetic nervous system activity. Curr Hypertens Rep. 1999;1:119–126
  35. Esler M, Lambert G, Brunner-La Rocca HP, Vaddadi G, Kaye D. Sympathetic nerve activity and neurotransmitter release in humans: translation from pathophysiology into clinical practice. Acta Physiol Scand. 2003;177:275–284
  36. Grassi G, Cattaneo BM, Seravalle G, Colombo M, Cavagnini F, Mancia G. Obesity and the sympathetic nervous system. Blood Press Suppl. 1996;1:43–46
  37. Lambert E, Straznicky N, Schlaich M, Esler M, Dawood T, Hotchkin E, et al. Differing pattern of sympathoexcitation in normal-weight and obesity-related hypertension. Hypertension. 2007;50:862–868
  38. Young JB, Rosa RM, Landsberg L. Dissociation of sympathetic nervous system activity in the rat. Evidence for nutrient-specific responses. Am J Physiol. 1984;247(1 Pt 1):E35–E40
  39. Goldstein DS. Plasma catecholamines and essential hypertension: an analytical review. Hypertension. 1983;5:86–99
  40. Goldstein DS. Catecholamines and stress. Endocr Regul. 2003;37:69–80
  41. Leonetti DL, Bergstrom RW, Shuman WO, Wahl PW, Jenner DA, Harrison GA, et al. Urinary catecholamines, plasma insulin and environmental factors in relation to body fat distribution. Int J Obes. 1991;15:345–357
  42. Widimsky J, Fejfarova MH, Fejfar Z. Changes of cardiac output in hypertensive disease. Cardiologia. 1957;31:381–389
  43. Eich RH, Peters RJ, Cuddy RP, Smulyan H, Lyons RH. Hemodynamics in labile hypertension. Am Heart J. 1962;63:188–195
  44. Finkielman S, Worcel M, Agrest A. Hemodynamic patterns in essential hypertension. Circulation. 1965;31:356–368
  45. Bello CT, Sevy RW, Harakal C. Varying hemodynamic patterns in essential hypertension. Am J Med Sci. 1965;250:24–35
  46. Eich RH, Cuddy RP, Smulyan H, Lyons RH. Hemodynamics in labile hypertension: follow-up study. Circulation. 1966;34:299–307
  47. Sannerstedt R. Hemodynamic response to exercise in patients with arterial hypertension. Acta Med Scand. 1966;180(Suppl. 458):1–83
  48. Lund-Johansen P. Twenty-year follow-up of hemodynamics in essential hypertension during rest and exercise. Hypertension. 1991;18(5 Suppl.):11154–11161
  49. Julius S, Pascual AV, London R. Role of parasympathetic inhibition in the hyperkinetic type of borderline hypertension. Circulation. 1971;44:413–418
  50. Julius S, Conway J. Hemodynamic studies in patients with borderline blood pressure elevation. Circulation. 1968;38:282–288
  51. Esler M, Julius S, Zweifler A, Randall O, Harburg E, Gardiner H, et al. Mild high-renin essential hypertension. Neurogenic human hypertension?. New Engl J Med. 1977;296:405–411
  52. Levy RL, White PD, Stroud WD, Hillman CC. Transient tachycardia: prognostic significance alone and in association with transient hypertension. JAMA. 1945;129:585–588
  53. Palatini P, Julius S. Heart rate and the cardiovascular risk. J Hypertens. 1997;15:3–17
  54. Lund-Johansen P, Omvik P. Hemodynamic patterns of untreated hypertensive disease. In:  Laragh JH,  Brenner BM editor. Hypertension: pathophysiology, diagnosis and management. 2nd ed. New York: Raven Press; 1995;p. 324–340
  55. Julius S, Randall OS, Esler MD, Kashima T, Ellis C, Bennet J. Altered cardiac responsiveness and regulation in the normal cardiac output type of borderline hypertension. Circulation Res. 1975;36(Suppl 1):199–207
  56. Egan B, Panis R, Hinderliter A, Schork N, Julius S. Mechanism of increased alpha-adrenergic vasoconstriction in human essential hypertension. J Clin Invest. 1987;80:812–817
  57. Kjeldsen SE, Zweifler AJ, Petrin J, Weder AB, Julius S. Sympathetic nervous system involvement in essential hypertension: increased platelet noradrenaline coincides with decreased beta-adrenoreceptor responsiveness. Blood Press; 1994;3:164–71
  58. Anderson EA, Sinkey CA, Lawton WJ, Mark AL. Elevated sympathetic nerve activity in borderline hypertensive humans. Evidence from direct intraneural recordings. Hypertension. 1989;14:177–183
  59. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Mancia G. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension. 1998;31:68–72
  60. Grassi G, Seravalle G, Trevano FQ, Dell'oro R, Bolla G, Cuspidi C, et al. Neurogenic abnormalities in masked hypertension. Hypertension. 2007;50:537–542
  61. Esler M, Lambert G, Vaz M, Thompson J, Kaye D, Kalff V, et al. Central nervous system monoamine neurotransmitter turnover in primary and obesity-related human hypertension. Clin Exp Hypertens. 1997;19:577–590
  62. Grassi G, Esler M. How to assess sympathetic activity in humans. J Hypertens. 1999;17:719–734
  63. Guzzetti S, Piccaluga E, Casati R, Cerutti S, Lombardi F, Pagani M, et al. Sympathetic predominance in essential hypertension: a study employing spectral analysis of heart rate variability. J Hypertens. 1988;6:711–717
  64. Grassi G, Vailati S, Bertinieri G, Seravalle G, Stella ML, Dell'Oro R, et al. Heart rate as marker of sympathetic activity. J Hypertens. 1998;16:1635–1639
  65. Julius S, Krause L, Schork NJ, Mejia AD, Jones KA, van de Ven C, et al Hyperkinetic borderline hypertension in Tecumseh. Michigan. J Hypertens. 1991;9:77–84
  66. Schork NJ, Weder AB, Schork MA, Bassett DR, Julius S. Disease entities, mixed multi-normal distributions, and the role of the hyperkinetic state in the pathogenesis of hypertension. Stat Med. 1990;9:301–314
  67. Palatini P, Casiglia E, Pauletto P, Staessen J, Kaciroti N, Julius S. Relationship of tachycardia with high blood pressure and metabolic abnormalities. A study with mixture analysis in three populations. Hypertension. 1997;30:1267–1273
  68. Grassi G. Renin-angiotensin-sympathetic crosstalks in hypertension: reappraising the relevance of peripheral interactions. J Hypertens. 2001;19:1713–1716
  69. Mancia G, Saino A, Grassi G. Interactions between the sympathetic nervous system and the renin angiotensin system. In:  Laragh JH,  Brenner BM editor. Hypertension, pathophysiology, diagnosis, and management. 2nd ed. New York: Raven Press, Ltd; 1995;p. 399–407
  70. Coote JH, Johns EJ, Macleod VH, Singer B. Effect of renal nerve stimulation, renal blood flow and adrenergic blockade on plasma renin activity in the cat. J Physiol. 1972;226:15–36
  71. Kiowski W, Julius S. Renin response to stimulation of cardiopulmonary mechanoreceptors in man. J Clin Invest. 1978;62:656–663
  72. Sweet CS, Kadowitz PJ, Brody MJ. Arterial hypertension elicited by prolonged intravertebral infusion of angiotensin II in conscious dog. Am J Physiol. 1971;221:1640–1644
  73. Andreatta SH, Averill DB, Santos RAS, Ferrario CM. The ventrolateral medulla. A new site of action of the renin-angiotensin system. Hypertension. 1988;11(Suppl I):163–166
  74. Mark AL, Abboud FM, Fitz AE. Influence of low- and high-pressure baroreceptors on plasma renin activity in humans. Am J Physiol. 1978;235:H29–H33
  75. Egan BM, Julius S, Cottier C, Osterziel KJ, Ibsen H. The role of cardiovascular receptors on the neural regulation of renin release in normal man. Hypertension. 1983;5:779–786
  76. Khairallah PA. Action of angiotensin on adrenergic nerve endings: inhibition of norepinephrine uptake. Federation Proc. 1972;31:1351–1357
  77. Cline WH. Enhanced in vivo responsiveness of presynaptic angiotensin II receptor-mediated facilitation of vascular adrenergic neurotransmission in spontaneously hypertensive rats. J Pharmacol Exp Ther. 1985;232:661–669
  78. Eikelis N, Esler M. The neurobiology of human obesity. Exp Physiol. 2005;90:673–682
  79. Vaz M, Jennings G, Turner A, Cox H, Lambert G, Esler M. Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects. Circulation. 1997;96:3423–3429
  80. Rumantir MS, Vaz M, Jennings GL, Collier G, Kaye DM, Seals DR, et al. Neural mechanisms in human obesity-related hypertension. J Hypertens. 1999;17:1125–1133
  81. Rocchini AP. The influence of obesity in hypertension. News Physiol Sci. 1990;5:245–249
  82. Hall JE. The kidney, hypertension and obesity. Hypertension. 2003;41:625–633
  83. Hall JE. Mechanisms of abnormal renal sodium handling in obesity hypertension. Am J Hypertens. 1997;10:S49–S55
  84. Schutz Y, Golay A, Felber JP, Jéquier E. Decreased glucose-induced thermogenesis after weight loss in obese subjects: a predisposing factor for relapse of obesity?. Am J Clin Nutr. 1984;39:380–387
  85. Golay A, Schutz Y, Broquet C, Moeri R, Felber JP, Jéquier E. Decreased thermogenic response to an oral glucose load in older subjects. J Am Geriatr Soc. 1983;31:144–148
  86. Landsberg L, Young JB, Leonard WK, Lisenmeire RA, Turek FW. Is obesity associated with lower body temperatures? Core temperature: a forgotten variable in energy balance. Metab Clin Exp. 2009;58:871–876
  87. Mellen PB, Gao SK, Vitolins MZ, Goff DC. Deteriorating eietary habits among adults with hypertension. DASH dietary accordance, NHANES 1988–1994 and 1999–2004. Arch Intern Med. 2008;168:308–314
  88. Mulrow CD, Chiquette E, Angel L, Grimm R, Cornell J, Summerbell CD, et al. WITHDRAWN: dieting to reduce body weight for controlling hypertension in adults. Cochrane Database Syst Rev. 2008;(4):CD 000484
  89. Kannel WB, Brand N, Skinner JJ, Dawber TR, McNamara PM. The relation of adiposity to blood pressure and development of hypertension. The Framingham study. Ann Intern Med. 1967;67:48–59
  90. Julius S, Valentini M, Palatini P. Overweight and hypertension: a 2-way street?. Hypertension. 2000;35:807–813
  91. Kawasaki T, Uezono K, Sanefuji M, Utsunomiya H, Fujino T, Kanaya S, et al. A 17-year follow-up study of hypertensive and normotensive male university students in Japan. Hypertens Res. 2003;26:445–452
  92. Jose AD, Collison D. The normal range and determinants of the intrinsic heart rate in man. Cardiovasc Res. 1970;4:160–167
  93. Glick G, Braunwald E. Relative roles of the sympathetic and parasympathetic nervous systems in the reflex control of heart rate. Circ Res. 1965;16:363–375
  94. Fagard RH, Stolarz K, Kuznetsova T, Seidlerova J, Tikhonoff V, Grodzicki T, et al. Sympathetic activity, assessed by power spectral analysis of HR variability, in white-coat, masked, and sustained hypertension versus true normotension. J Hypertens. 2007;25:2280–2285
  95. Carmelli D, Robinette D, Fabsitz R. Concordance, discordance and prevalence of hypertension in World War II. J Hypertens. 1994;12:323–328
  96. Flaa A, Eide IK, Kjeldsen SE, Rostrup M. Sympathoadrenal stress reactivity is a predictor of future blood pressure: an 18-year follow-up study. Hypertension. 2008;52:336–341
  97. Masuo K, Mikami H, Ogihara T, Tuck ML. Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young, nonobese Japanese population. Am J Hypertens. 1997;10:77–83
  98. Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension. 2003;42L:474–480
  99. Flaa A, Sandvik L, Kjeldsen SE, Eide IK, Rostrup M. Does sympathoadrenal activity predict changes in body fat? An 18-y follow-up study. Am J Clin Nutr. 2008;87:1596–1601
  100. Bertel O, Bühler FR, Kiowski W, Lütold BE. Decreased beta-adrenoreceptor responsiveness as related to age, blood pressure, and plasma catecholamines in patients with essential hypertension. Hypertension. 1980;2:130–138
  101. Jennings G, Bobik A, Esler M, Korner P. Contribution of cardiovascular reflexes to differences in beta-adrenoceptor-mediated responses in essential hypertension. Clin Sci. 1981;61(Suppl 7):177s–180s
  102. Volpe M, Trimarco B, Ricciardelli B, Rengo F, Chiariello M, Cuocolo A, et al. Effects of salt loading on the response to isoproterenol in normal and hypertensive subjects. Cardiologia. 1982;27:453–461
  103. Feldman RD, Chorazyczewski J. G-protein function is reduced in hypertension. Hypertension. 1997;29:422–427
  104. Valentini M, Julius S, Palatini P, Brook RD, Bard RL, Bisognano JD, et al. Attenuation of haemodynamic, metabolic and energy expenditure responses to isoproterenol in patients with hypertension. J Hypertens. 2004;22:1999–2006
  105. Julius S, Jamerson K. Sympathetics insulin resistance and coronary risk in hypertension: the “chicken-and-egg” question. J Hypertens. 1994;12:495–502
  106. Lowell BB, Bachman ES. β-adrenergic receptors, diet-induced thermogenesis, and obesity. J Biol Chem. 2003;278:29385–29388
  107. Green SA, Cole G, Jacinto M, Innis M, Ligget SB. A polymorphism of the human beta2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem. 1993;268:23116–23121
  108. Reihsaus E, Innis M, MacIntyre N, Ligget SB. Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol. 1993;8:334–339
  109. Kotanko P, Hőlinger O, Skrabat F. β-2 adrenoceptor density in fibroblast culture correlates with human NaCl sensitivity. Am J Physiol. 1992;263:C623–C627
  110. Svetkey LP, Chen Y-T, Mckeown SP, Preis L, Wilson AF. Preliminary evidence of linkage of salt sensitivity in black Americans at the β-2 adrenergic receptor locus. Hypertension. 1997;29:918–922
  111. Kotanko P, Binder A, Tasker J, Defreitas P, Kamdar S, Clark AJL, et al. Essential hypertension in African Caribbean associates with a variant of the β2-adrenoceptor. Hypertension. 1997;30:773–776
  112. Timmermann B, Mo R, Luft FC, Gerdts E, Busjahn , Omvik P, et al. β-2 Adrenoceptor genetic variation is associated with genetic predisposition to essential hypertension: the Bergen Blood Pressure Study. Kidney Int. 1998;53:1455–1460
  113. Gratze G, Fortin J, Labugger R, Binder A, Kotanko P, Timmermann B, et al. B-2 adrenergic receptor variants affect resting blood pressure and agonist-induced vasodilation in young adult Caucasians. Hypertension. 1999;33:1425–1430
  114. Busjahn A, Li G-H, Faulhaber H-D, Rosenthal M, Becker A, Jeschke E, et al. β2-adrenergic receptor gene variations, blood pressure, and heart size in normal twins. Hypertension. 2000;35:555–560
  115. Bengtsson K, Orho-Melander M, Melander O, Lindblad U, Ranstam J, Ranstam L, et al. β2-adrenergic receptor gene variation and hypertension in subjects with type 2 diabetes. Hypertension. 2001;37:1303–1308
  116. Castellano M, Rossi F, Giacchè M, Perani C, Rivadosi F, Muiesan ML. β2- adrenergic receptor gene polymorphism, age, and cardiovascular phenotypes. Hypertension. 2003;41:361–367
  117. Pereira AC, Floriano MS, Mota GFA, Cunha RD, Herkenhoff FL, Mill JG, et al. β2 adrenoceptor functional gene variants, obesity, and blood pressure level interactions in the general population. Hypertension. 2003;42(Part 2):685–692
  118. Masuo K, Katsuya T, Fu X, Rakugi H, Ogihara T, Tuck M. β2- and β3- adrenergic receptor polymorphisms are related to the onset of weight gain and blood pressure elevation over 5 years. Circulation. 2005;11:3429–3434
  119. Eisenach JH, Schroeder DR, Pike TL, Johnson CP, Schrage WG, Snyder EM, et al. Dietary sodium restriction and beta-2 adrenergic receptor polymorphism modulate cardiovascular function in humans. J Physiol. 2006;574:955–965
  120. Masuo K, Katsuya T, Kawaguchi H, Fu Y, Rakugi H, Ogihara T, et al. Rebound weight gain as associated with high plasma norepinephrine levels that are mediated through polymorphisms in the beta2-adrenergic receptor. Am J Hypertens. 2005;18:1508–1516
  121. Kawaguchi H, Masuo K, Katsuya T, Sugimoto K, Rakugi H, Ogihara T, et al. β2- and β3-adrenoceptor polymorphisms relate to subsequent weight gain and blood pressure elevation in obese normotensive individuals. Hypertens Res. 2006;29:951–959
  122. Garovic VD, Joyner MJ, Dietz NM, Boerwinkle E, Turner ST. β2- adrenergic receptor polymorphism and nitric oxide-dependent forearm blood flow responses to isoproterenol in humans. J Physiol. 2003;546:583–589
  123. Narkiewicz K, Somers VK. The sympathetic nervous system and obstructive sleep apnea: implications for hypertension. J Hypertens. 1997;15:1613–1619
  124. Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest. 1995;96:1897–1904
  125. Kraiczi H, Hedner J, Peker Y, Carlson J. Increased vasoconstrictor sensitivity in obstructive sleep apnea. J Appl Physiol. 2000;89:493–498
  126. Fletcher EC. Sympathetic over activity in the etiology of hypertension of obstructive sleep apnea. Sleep. 2003;1:15–19
  127. Mortimore IL, Marshall I, Wraith PK, Sellar RJ, Douglas NJ. Neck and total body fat deposition in nonobese and obese patients with sleep apnea compared with that in control subjects. Am J Respir Crit Care Med. 1998;157:280–283
  128. Grassi G, Facchini A, Trevano FQ, Dell'Oro R, Arenare F, Tana F, et al. Obstructive sleep apnea-dependent and -independent adrenergic activation in obesity. Hypertension. 2005;46:321–325
  129. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;373:425–432
  130. Haynes WG. Role of leptin in obesity-related hypertension. Exp Physiol. 2005;90:683–688
  131. Eikelis N, Schlaich M, Aggarwal A, Kaye D, Esler M. Interactions between leptin and the human sympathetic nervous system. Hypertension. 2003;41:1072–1079
  132. Gusmao Correia ML, Haynes WG. Leptin, obesity and cardiovascular disease. Curr Opin Nephrol Hypertens. 2004;13:215–223
  133. Jackson EK, Li P. Human leptin has natriuretic activity in the rat. Am J Physiol. 1997;272:F333–F338
  134. Hall JE, Hildebrandt DA, Kuo J. Obesity hypertension: role of leptin and sympathetic nervous system. Am J Hypertens. 2001;14:103S–115S
  135. Carlyle M, Jones OB, Kuo JJ, Hall JE. Chronic cardiovascular and renal actions of leptin: role of adrenergic activity. Hypertension. 2002;39:496–501
  136. Kim S, Whelan J, Claycombe K, Reath DB, Moustaid-Moussa N. Angiotensin II increases leptin secretion by 3T3-L1 and human adipocytes via a prostaglandin-independent mechanism. J Nutr. 2002;132:1135–1140
  137. Frühbeck G. Pivotal role of nitric oxide in the control of blood pressure after leptin administration. Diabetes. 1999;48:903–908
  138. Nakagawa K, Higashi Y, Sasaki S, Oshima T, Matsuura H, Chayama K. Leptin causes vasodilation in humans. Hypertens Res. 2002;25:161–165
  139. Gardiner SM, Kemp PA, March JE, Bennett T. Regional haemodynamic effects of recombinant murine or human leptin in conscious rats. Br J Pharmacol. 2000;130:805–810
  140. Rahmouni K, Jalali A, Morgan DA, Haynes WG. Lack of dilator effect of leptin in the hindlimb vascular bed of conscious rats. Eur J Pharmacol. 2005;518:175–181
  141. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem. 1995;270:26746–26749
  142. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun. 1996;221:286–289
  143. Côté M, Mauriège P, Bergeron J, Alméras N, Tremblay A, Lemieux I, et al. Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. J Clin Endocrinol Metab. 2005;90:1434–1439
  144. Imatoh T, Miyazaki M, Momose Y, Tanihara S, Une H. Adiponectin levels associated with the development of hypertension: a prospective study. Hypertens Res. 2008;31:229–233
  145. Li HY, Chiu YF, Hwu CM, Sheu WH, Hung YJ, Fujimoto W, et al. The negative correlation between plasma adiponectin and blood pressure depends on obesity: a family-based association study in SAPPHIRe. Am J Hypertens. 2008;21:471–476
  146. Tanida M, Shen J, Horii Y, Matsuda M, Kihara S, Funahashi T, et al. Effects of adiponectin on the renal sympathetic nerve activity and blood pressure in rats. Exp Biol Med (Maywood). 2007;232:390–397
  147. Hoyda TD, Smith PM, Ferguson AV. Adiponectin acts in the nucleus of the solitary tract to decrease blood pressure by modulating the excitability of neuropeptide Y neurons. Brain Res. 2009;1256:76–84
  148. Nowak L, Adamczak M, Wiecek A. Blockade of sympathetic nervous system activity by rilmenidine increases plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens. 2005;18:1470–1475
  149. Barton DA, Dawood T, Lambert EA, Esler MD, Haikerwal D, Brenchley C, et al. Sympathetic activity in major depressive disorder: identifying those at increased cardiac risk?. J Hypertens. 2007;25:2117–2124
  150. Lambert E, Hotchkin E, Alvarenga M, Pier C, Richards J, Barton D, et al. Single-unit analysis of sympathetic nervous discharges in patients with panic disorder. J Physiol. 2006;570:637–643
  151. Julius S, Nesbitt S. Clinical consequences of the autonomic imbalance in hypertension and congestive heart failure. Scand Cardiovasc J Suppl. 1998;47:23–30
  152. Bakris GL, Hart P, Ritz E. Beta blockers in the management of chronic kidney disease. Kidney Int. 2006;70:1905–1913
  153. Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC. Hypothesis: beta-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension. 2001;37:250–254
  154. Messerli FH, Bell DS, Fonseca V, Katholi RE, Mc Gll JB, Phillips RA, et al. Body weight changes with beta-blocker use: results from GEMINI. Am J Med. 2007;120:610–615
  155. Wofford MR, Anderson DC, Brown CA, Jones DW, Miller ME, Hall JE. Antihypertensive effect of alpha and beta adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens. 2001;14:694–698
  156. Reisin E, Jack AV. Obesity and hypertension: mechanisms, cardio-renal consequences, and therapeutic approaches. Med Clin North Am. 2009;93:733–751
  157. Redon J, Cifkova R, Laurent S, Nilsson P, Narkiewicz K, Erdine S, et al. Scientific Council of the European Society of Hypertension. The metabolic syndrome in hypertension: European society of hypertension position statement. J Hypertens. 2008;26:1891–1900

PII: S1933-1711(09)00136-3

doi: 10.1016/j.jash.2009.10.001

Journal of the American Society of Hypertension
Volume 3, Issue 6 , Pages 353-365 , November 2009

Article Tools

* Image Usage & Resolution